Adia Nutrition files final IRB protocol for back pain study

Single-blind trial of IV AdiaVita for lower back pain will enroll 100 adults, with a $5,000 patient-pay model and crossover design, pending IRB approval.

Published on Mar. 3, 2026

Got story updates? Submit your updates here. ›

Adia Nutrition Inc. (OTCQB: ADIA), a company focused on regenerative medicine and therapeutic solutions, has submitted the final revised protocol to the Institutional Review Board (IRB) for a lower back pain clinical study using its AdiaVita product. The single-blind, placebo-controlled trial will randomize approximately 100 participants, with the primary objective of evaluating AdiaVita's potential to reduce inflammation and support tissue repair in the lower back. The study will have a crossover design, allowing the placebo group to receive AdiaVita in the subsequent phase.

Why it matters

This study continues Adia Nutrition's progress in advancing regenerative medicine solutions, following the ongoing IRB-approved trial examining AdiaVita's use in treating Autism Spectrum Disorder. The lower back pain study aims to provide evidence for a less invasive, systemic IV delivery of AdiaVita as an alternative to conventional targeted injections for managing lower back pain.

The details

The key features of the lower back pain study include a single-blind, placebo-controlled design randomizing approximately 100 participants into two groups - one receiving AdiaVita via intravenous (IV) administration and the other receiving a placebo. The primary objective is to evaluate AdiaVita's potential to reduce inflammation and support repair of damaged tissue in the lower back. The crossover design will allow the placebo group to receive AdiaVita in the subsequent phase for additional data and extended follow-up. The patient-pay model remains $5,000 per participant, with no additional cost for the crossover phase.

  • The initial protocol submission was on February 16, 2026.
  • The final revised protocol was submitted in March 2026.

The players

Adia Nutrition Inc.

A publicly traded company advancing healthcare through innovation, specializing in sales of stem cell and regenerative products, and expanding nationwide with Adia Med clinics offering regenerative treatments.

Adia Med of Winter Park, LLC

A subsidiary of Adia Nutrition that has submitted the final revised protocol for the lower back pain clinical study.

Larry Powalisz

The CEO of Adia Nutrition.

Got photos? Submit your photos here. ›

What they’re saying

“We appreciate the IRB's positive and detailed feedback on the initial draft, which has helped us refine and strengthen the protocol. With the final revised version now submitted, we are optimistic about receiving approval soon and moving forward with this important study on AdiaVita's potential in managing lower back pain through straightforward IV delivery.”

— Larry Powalisz, CEO of Adia Nutrition (Newsfile Corp.)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.